301 related articles for article (PubMed ID: 36311750)
1. Immune-infiltrating signature-based classification reveals CD103
Luo Y; Zong Y; Hua H; Gong M; Peng Q; Li C; Neculai D; Zeng X
Front Immunol; 2022; 13():1011590. PubMed ID: 36311750
[TBL] [Abstract][Full Text] [Related]
2. Comprehensive Analysis of a Cancer-Immunity Cycle-Based Signature for Predicting Prognosis and Immunotherapy Response in Patients With Colorectal Cancer.
Hou Y; Zhang R; Zong J; Wang W; Zhou M; Yan Z; Li T; Gan W; Lv S; Zeng Z; Yang M
Front Immunol; 2022; 13():892512. PubMed ID: 35711437
[TBL] [Abstract][Full Text] [Related]
3. Identification of necroptosis-related lncRNAs for prognosis prediction and screening of potential drugs in patients with colorectal cancer.
Chen ZH; Lin YL; Chen SQ; Yang XY
World J Gastrointest Oncol; 2023 Nov; 15(11):1951-1973. PubMed ID: 38077636
[TBL] [Abstract][Full Text] [Related]
4. Integration of single-cell RNA sequencing and bulk RNA transcriptome sequencing reveals a heterogeneous immune landscape and pivotal cell subpopulations associated with colorectal cancer prognosis.
Zhang Q; Liu Y; Wang X; Zhang C; Hou M; Liu Y
Front Immunol; 2023; 14():1184167. PubMed ID: 37675100
[TBL] [Abstract][Full Text] [Related]
5. Development of a novel hypoxia-immune-related LncRNA risk signature for predicting the prognosis and immunotherapy response of colorectal cancer.
Luan L; Dai Y; Shen T; Yang C; Chen Z; Liu S; Jia J; Li Z; Fang S; Qiu H; Cheng X; Yang Z
Front Immunol; 2022; 13():951455. PubMed ID: 36189298
[TBL] [Abstract][Full Text] [Related]
6. Identification and Validation of the Glycolysis and Immune-related Gene Signature for Prognosis in Colorectal Cancer.
Jiang M; Liu Y; Xu J; Xu Z; Ye T; Li S; Jiang C
Anticancer Res; 2024 Jan; 44(1):117-131. PubMed ID: 38159970
[TBL] [Abstract][Full Text] [Related]
7. Tumor microenvironment characterization in colorectal cancer to identify prognostic and immunotherapy genes signature.
Guo XW; Lei RE; Zhou QN; Zhang G; Hu BL; Liang YX
BMC Cancer; 2023 Aug; 23(1):773. PubMed ID: 37596528
[TBL] [Abstract][Full Text] [Related]
8. Cross-Talk Between m
Song W; Ren J; Xiang R; Yuan W; Fu T
Front Immunol; 2022; 13():740960. PubMed ID: 35350786
[TBL] [Abstract][Full Text] [Related]
9. A pyroptosis-related signature in colorectal cancer: exploring its prognostic value and immunological characteristics.
Jiang P; Fan J; Huang S; Liu L; Bai M; Sun Q; Shen J; Zhang N; Liu D; Zhou N; Feng Y; Jiang J; Zhu J
PeerJ; 2023; 11():e16631. PubMed ID: 38144182
[TBL] [Abstract][Full Text] [Related]
10. Immune-related gene-based prognostic index for predicting survival and immunotherapy outcomes in colorectal carcinoma.
Liang Z; Sun R; Tu P; Liang Y; Liang L; Liu F; Bian Y; Yin G; Zhao F; Jiang M; Gu J; Tang D
Front Immunol; 2022; 13():944286. PubMed ID: 36591255
[TBL] [Abstract][Full Text] [Related]
11. CD103 and CD39 coexpression identifies neoantigen-specific cytotoxic T cells in colorectal cancers with low mutation burden.
van den Bulk J; van der Ploeg M; Ijsselsteijn ME; Ruano D; van der Breggen R; Duhen R; Peeters KCMJ; Fariña-Sarasqueta A; Verdegaal EME; van der Burg SH; Duhen T; de Miranda NFCC
J Immunother Cancer; 2023 Feb; 11(2):. PubMed ID: 36792124
[TBL] [Abstract][Full Text] [Related]
12. Single-cell dissection reveals the role of DNA damage response patterns in tumor microenvironment components contributing to colorectal cancer progression and immunotherapy.
Shen X; Mo S; Wang Y; Lin L; Liu Y; Weng M; Gu W; Nakajima T
Genes Cells; 2023 May; 28(5):348-363. PubMed ID: 36811212
[TBL] [Abstract][Full Text] [Related]
13. Subtyping of microsatellite stability colorectal cancer reveals guanylate binding protein 2 (GBP2) as a potential immunotherapeutic target.
Wang H; Zhou Y; Zhang Y; Fang S; Zhang M; Li H; Xu F; Liu L; Liu J; Zhao Q; Wang F
J Immunother Cancer; 2022 Apr; 10(4):. PubMed ID: 35383115
[TBL] [Abstract][Full Text] [Related]
14. Characterization of stem cell landscape and identification of stemness-relevant prognostic gene signature to aid immunotherapy in colorectal cancer.
Zheng H; Liu H; Li H; Dou W; Wang J; Zhang J; Liu T; Wu Y; Liu Y; Wang X
Stem Cell Res Ther; 2022 Jun; 13(1):244. PubMed ID: 35681225
[TBL] [Abstract][Full Text] [Related]
15. CD103
Corgnac S; Malenica I; Mezquita L; Auclin E; Voilin E; Kacher J; Halse H; Grynszpan L; Signolle N; Dayris T; Leclerc M; Droin N; de Montpréville V; Mercier O; Validire P; Scoazec JY; Massard C; Chouaib S; Planchard D; Adam J; Besse B; Mami-Chouaib F
Cell Rep Med; 2020 Oct; 1(7):100127. PubMed ID: 33205076
[TBL] [Abstract][Full Text] [Related]
16. A comprehensive multi-omics analysis identifies a robust scoring system for cancer-associated fibroblasts and intervention targets in colorectal cancer.
Wang F; Li Z; Xu T; Zhang Q; Ma T; Li S; Wang X
J Cancer Res Clin Oncol; 2024 Mar; 150(3):124. PubMed ID: 38478111
[TBL] [Abstract][Full Text] [Related]
17. An immune landscape based prognostic signature predicts the immune status and immunotherapeutic responses of patients with colorectal cancer.
Li M; Li W; Yang X; Wang H; Peng Y; Yin J; Lu Y; Liu L; Shang J; Zhao Q
Life Sci; 2020 Nov; 261():118368. PubMed ID: 32888940
[TBL] [Abstract][Full Text] [Related]
18. Complement downregulation promotes an inflammatory signature that renders colorectal cancer susceptible to immunotherapy.
Krieg C; Weber LM; Fosso B; Marzano M; Hardiman G; Olcina MM; Domingo E; El Aidy S; Mallah K; Robinson MD; Guglietta S
J Immunother Cancer; 2022 Sep; 10(9):. PubMed ID: 36137652
[TBL] [Abstract][Full Text] [Related]
19. Constructing a Tregs-associated signature to predict the prognosis of colorectal cancer patients: A STROBE-compliant retrospective study.
Ping G; Tian Y; Zhou Z
Medicine (Baltimore); 2022 Nov; 101(47):e31382. PubMed ID: 36451426
[TBL] [Abstract][Full Text] [Related]
20. Immune effector dysfunction signatures predict outcomes in patients with colorectal cancer.
Tang H; Wu H; Jian Y; Ji T; Wu B; Wu Y; Wang P; Cao T
Int Immunopharmacol; 2024 May; 132():111949. PubMed ID: 38552290
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
